Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib with Chemoradiation for Locally Advanced Head and Neck Cancer
NCT00193284Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Oct 2003
- Primary completion
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gefitinib in squamous cell carcinoma of the head and neck (HNSCC) (2 cohorts), sponsored by SCRI Development Innovations. Primary endpoint: Overall Response Rate. Started Oct 2003; status: completed.
02
Drugs
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00193284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193284.